Figure 6: Drp1-K38A restores DA release in the MPTP pre-lesioned mice.
From: Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo
(a) Approximately 10-week-old C57Bl/6 mice were injected with MPTP (20 mg kg−1, i.p. once daily for 5 days) or saline and 7 days after the last injection, rAAV2 was delivered to the SNc 8 weeks before in vivo microdialysis. KCl-evoked DA release was performed as described in Fig. 3. Data represent mean±s.e.m. (two-way analysis of variance: F1,13=11.89, P=0.004, n=4–5 mice per group, followed by Newman–Keuls post-hoc test, *P=0.001 (MPTP-K38A versus MPTP-GFP), #P=0.003 (MPTP-K38A versus Saline-K38A). (b) Representative HPLC chromatograms of the 30-min fractions of a. After microdialysis, brains were removed and processed for stereological cell counting (c,d), total striatal DA content (e) and striatal DA terminals (f).
